Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in health...
Saved in:
Published in | Revista española de quimioterapia Vol. 32 Suppl 1; no. Suppl 1; pp. 19 - 24 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Spain
Sociedad Española de Quimioterapia
01.05.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L. |
---|---|
AbstractList | Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to
Enterobacterales
and
Pseudomonas aeruginosa
. As PK/PD targets, we selected %T
>MIC
> 70% for all pathogens, and AUC
24
/MIC > 24 and AUC
24
/MIC > 15 for net stasis of
Enterobacterales
and
P. aeruginosa
, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for
Enterobacterales
and
Staphylococcus
spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T
>MIC
and AUC
24
/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for
P. aeruginosa
with MICs of 256-512 mg/L. Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L. Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L. |
Author | Canut-Blasco, A Rodríguez-Gascón, A |
Author_xml | – sequence: 1 givenname: A surname: Rodríguez-Gascón fullname: Rodríguez-Gascón, A – sequence: 2 givenname: A surname: Canut-Blasco fullname: Canut-Blasco, A email: andres.canutblasco@osakidetza.eus organization: Andrés Canut-Blasco. Microbiology Service, Edificio Consultas Externas, Hospital Universitario de Álava. c/Francisco Leandro de Viana, s/n. 01009. Vitoria-Gasteiz, Spain. andres.canutblasco@osakidetza.eus |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31131588$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkMtOwzAQRS1URB_wC6hLNpE8fiT2BoTKU6rEBtaW49itIbFDnCD17wmiVGU1M3dG517NHE1CDPYEzUAKkUkOYnLUT9E8pXeMGWUSztCUAlDgQszQzZ01vt3azofNst3qrtEmfvhge2_SUofqIFa7oJsfMbqli8nFZmd8OEenTtfJXuzrAr093L-unrL1y-Pz6nadtSTP-6yUpCAmx9KVGLuSisKC1XgMAQxsoQWuCiOKklW5LLFkuRhHapnj3ADWhC7Q9S-3HcrGVsaGvtO1ajvf6G6novbq_yb4rdrEL5VzziGnI-BqD-ji52BTrxqfjK1rHWwckiKEEgABwMbTy2Ovg8nf1-g3MIds1Q |
ContentType | Journal Article |
Copyright | The Author 2019 2019 |
Copyright_xml | – notice: The Author 2019 2019 |
DBID | CGR CUY CVF ECM EIF NPM 7X8 5PM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1988-9518 |
EndPage | 24 |
ExternalDocumentID | PMC6555163 31131588 |
Genre | Journal Article Review |
GroupedDBID | --- 123 2WC ADBBV AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CGR CUY CVF DIK EBD EBS ECM EIF EJD EML F5P FRP GROUPED_DOAJ GX1 HYE NPM OK1 RPM W2D 7X8 5PM EMOBN M~E SV3 |
ID | FETCH-LOGICAL-p266t-b9272c609fb00fb387e1ea0315141e7a80d7c87b4d69b094687c83e4f55c10a23 |
ISSN | 1988-9518 0214-3429 |
IngestDate | Thu Aug 21 18:34:30 EDT 2025 Fri Jul 11 10:16:14 EDT 2025 Thu May 23 23:47:52 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
License | The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/) |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p266t-b9272c609fb00fb387e1ea0315141e7a80d7c87b4d69b094687c83e4f55c10a23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6555163 |
PMID | 31131588 |
PQID | 2232118114 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555163 proquest_miscellaneous_2232118114 pubmed_primary_31131588 |
PublicationCentury | 2000 |
PublicationDate | 2019-May 20190501 |
PublicationDateYYYYMMDD | 2019-05-01 |
PublicationDate_xml | – month: 05 year: 2019 text: 2019-May |
PublicationDecade | 2010 |
PublicationPlace | Spain |
PublicationPlace_xml | – name: Spain |
PublicationTitle | Revista española de quimioterapia |
PublicationTitleAlternate | Rev Esp Quimioter |
PublicationYear | 2019 |
Publisher | Sociedad Española de Quimioterapia |
Publisher_xml | – name: Sociedad Española de Quimioterapia |
SSID | ssj0043491 |
Score | 2.2614105 |
SecondaryResourceType | review_article |
Snippet | Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 19 |
SubjectTerms | Animals Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacterial Infections - drug therapy Bacterial Infections - microbiology Current Key Topics in Fosfomycin Fosfomycin - pharmacokinetics Fosfomycin - pharmacology Fosfomycin - therapeutic use Humans |
Title | Deciphering pharmacokinetics and pharmacodynamics of fosfomycin |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31131588 https://www.proquest.com/docview/2232118114 https://pubmed.ncbi.nlm.nih.gov/PMC6555163 |
Volume | 32 Suppl 1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELaaHKpcqvS9fcmVqlyIqzU2Bk5V82ijSqm21UbKbWUbk6J2gXThsPn1HWNYWJpDmwva9S4I-Rt9nvH4m0HonbarICw7hAH9E-5LQWBZYETzMJLGFpRqmvadfxVnF_zLZXDZHx1q1CWVeq9vbtWV3AVVGANcrUr2P5DdPBQG4DPgC1dAGK7_hPGJ0VnZCPiuvLKtQf0T3MZN6eVuMHF955tjG2kBjupyrduS211xbqsyr6RngGFs8vyIQszrJca7rrNlVlidcpltKPx7kbgU-8lVbW7IZ7nSzU3MFST4ZfdK-uxGXlfkCLx0XXRHKF16fmvLwaqcguGWQ3OeNJGJdzp-pW9_vZJjMp9yawyOG41j2hjABPcuGlJxv9VZWykM-OEeHbBrS65unXbS6wHK5bKBmVHKaOB6BY5Kac_Oj0VgM4NsB-0wyrsI3C3cnHHXYLF72z10v3vYbfHH-BjtwC-Z76MHbUCBPzrreIjumfwROpg54NeHeN4L7FaH-ADP-lrl68fow8CE8NiEMJgQHpsQLlLcm9ATdPHpdH58RtqeGqQEV6wiKvZDX4tpnALfpopFoaFG2lYflFMTymiahDoKFU9ErCD0FxF8ZYanQaDpVPrsKdrNi9w8Rzg2KQTrqRAR1TyWXCaxURLi62molIjkBL3t5mwBnGUTUTI3Rb1aADf4VvBM-QQ9c3O4KF1xlUU34xMUbs3u5g-2Hvr2L3n2o6mL3mL74s53vkR7vbm_QrvV79q8Bp-zUm8aS_kDwDWI5w |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deciphering+pharmacokinetics+and+pharmacodynamics+of+fosfomycin&rft.jtitle=Revista+espa%C3%B1ola+de+quimioterapia&rft.au=Rodr%C3%ADguez-Gasc%C3%B3n%2C+Alicia&rft.au=Canut-Blasco%2C+Andr%C3%A9s&rft.date=2019-05-01&rft.pub=Sociedad+Espa%C3%B1ola+de+Quimioterapia&rft.issn=0214-3429&rft.eissn=1988-9518&rft.volume=32&rft.issue=Suppl+1&rft.spage=19&rft.epage=24&rft_id=info%3Apmid%2F31131588&rft.externalDocID=PMC6555163 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1988-9518&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1988-9518&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1988-9518&client=summon |